Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies

Immune checkpoint blockade therapies (ICBs) are a prominent breakthrough in cancer immunotherapy in recent years (named the 2013 “Breakthrough of the Year” by the Science magazine). Thus far, FDA-approved ICBs primarily target immune checkpoints CTLA-4, PD-1, and PD-L1. Notwithstanding their impress...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Hongxing, Yang, Eddy Shih-Hsin, Conry, Marty, Fiveash, John, Contreras, Carlo, Bonner, James A., Shi, Lewis Zhichang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997608/
https://www.ncbi.nlm.nih.gov/pubmed/32042863
http://dx.doi.org/10.1016/j.gendis.2019.06.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997608/
https://www.ncbi.nlm.nih.gov/pubmed/32042863
http://dx.doi.org/10.1016/j.gendis.2019.06.006

Ejemplares similares